These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 30306109)

  • 1. Occurrence of an invasive cervical epidermoid carcinoma in a patient receiving TNF-α blocking therapy for hidradenitis suppurativa.
    Ram A; Noël JC; Marmol VD; Benhadou F
    JAAD Case Rep; 2018 Oct; 4(9):857-859. PubMed ID: 30306109
    [No Abstract]   [Full Text] [Related]  

  • 2. Metastatic squamous cell carcinoma in a patient treated with adalimumab for hidradenitis suppurativa.
    Giesey R; Delost GR; Honaker J; Korman NJ
    JAAD Case Rep; 2017 Nov; 3(6):489-491. PubMed ID: 29022006
    [No Abstract]   [Full Text] [Related]  

  • 3. Acute Erythroderma in a Patient Receiving TNF-α-Blocking Therapy for Hidradenitis Suppurativa.
    Benhadou F; Hellgren G; Willaert F; Del Marmol V
    Case Rep Dermatol; 2018; 10(1):7-12. PubMed ID: 29515388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant psoriasis and hidradenitis suppurativa responsive to adalimumab therapy: A case series.
    Yen CF; Huang YH; Chi CC
    Indian J Dermatol Venereol Leprol; 2021; 87(2):223-226. PubMed ID: 31389375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Observational case series on adalimumab-induced paradoxical hidradenitis suppurativa.
    Delobeau M; Abdou A; Puzenat E; Deveza E; Biver-Dalle C; van de Laak A; Roche-Kubler B; Vuitton L; Koch S; Wendling D; Aubin F
    J Dermatolog Treat; 2016; 27(3):251-3. PubMed ID: 26368546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
    Lovrić I; Brkić J; Ćorluka M; Čović M; Pejić J; Zeljko Penavić J
    Acta Dermatovenerol Croat; 2021 Jul; 29(2):108-110. PubMed ID: 34477078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Squamous cell carcinoma of the cervix arising in a patient on adalimumab � a need for cervical screenings in patients on tumor necrosis factor inhibitors.
    Bessaleli E; Scheinfeld N; Kroumpouzos- G
    Dermatol Online J; 2018 May; 24(5):. PubMed ID: 30142745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paradoxical Hidradenitis Suppurativa in Patients Receiving TNF-α Inhibitors: Case Series, Systematic Review, and Case Meta-Analysis.
    Salvador-Rodriguez L; Montero-Vílchez T; Arias-Santiago S; Molina-Leyva A
    Dermatology; 2020; 236(4):307-313. PubMed ID: 32135533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A complication in a patient with hidradenitis suppurativa taking adalimumab.
    Perez OD; Tarazi M; Husain S; Makkar J; Gallitano SM
    JAAD Case Rep; 2022 Sep; 27():147-150. PubMed ID: 36051225
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of lichen planopilaris with adalimumab in a patient with hidradenitis suppurativa and rheumatoid arthritis.
    Alam MS; LaBelle B
    JAAD Case Rep; 2020 Mar; 6(3):219-221. PubMed ID: 32123715
    [No Abstract]   [Full Text] [Related]  

  • 11. Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients.
    Savage KT; Santillan MR; Flood KS; Charrow A; Porter ML; Kimball AB
    JAAD Case Rep; 2020 Feb; 6(2):99-102. PubMed ID: 31993474
    [No Abstract]   [Full Text] [Related]  

  • 12. Metabolic, pharmacokinetic, and toxicological issues of biologic therapies currently used in the treatment of hidradenitis suppurativa.
    Molinelli E; Sapigni C; Campanati A; Brisigotti V; Offidani A
    Expert Opin Drug Metab Toxicol; 2020 Nov; 16(11):1019-1037. PubMed ID: 32896186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spotlight on adalimumab in the treatment of active moderate-to-severe hidradenitis suppurativa.
    Fotiadou C; Vakirlis E; Ioannides D
    Clin Cosmet Investig Dermatol; 2016; 9():367-372. PubMed ID: 27799806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Single Nucleotide Polymorphisms of the Promoter of the TNF Gene on Adalimumab Treatment Responses in Hidradenitis Suppurativa.
    Argyropoulou M; Trigoni A; Kaffenberger J; Stergianou D; Damoraki G; Mingiani E; Micha S; Krispinsky A; Meltzanidou P; Kanni T; Lazaridou E; Giamarellos-Bourboulis EJ
    Dermatology; 2023; 239(5):746-752. PubMed ID: 37331331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
    Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD
    J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case paradoxical hidradenitis suppurativa with janus kinase inhibitor, literature review and pooled analysis of biological agent-induced HS.
    Shaharir SS; Jamil A; Chua SH; Arumugam M; Rosli N
    Dermatol Ther; 2020 Nov; 33(6):e14021. PubMed ID: 32677247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-savings of adalimumab in hidradenitis suppurativa: a retrospective analysis of a real-world cohort.
    Argyropoulou M; Kanni T; Kyprianou M; Melachroinopoulos N; Giamarellos-Bourboulis EJ
    Br J Dermatol; 2019 May; 180(5):1161-1168. PubMed ID: 30192377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hidradenitis suppurativa managed with adalimumab.
    Yamauchi PS; Mau N
    J Drugs Dermatol; 2009 Feb; 8(2):181-3. PubMed ID: 19213236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor Necrosis Factor Inhibitors in Inflammatory Bowel Disease and Risk of Immune Mediated Inflammatory Diseases.
    Ward D; Nyboe Andersen N; Gørtz S; Thorn Iversen A; Højgaard Allin K; Beaugerie L; Kirchgesner J; Jess T
    Clin Gastroenterol Hepatol; 2024 Jan; 22(1):135-143.e8. PubMed ID: 37442315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secukinumab in the treatment of hidradenitis suppurativa.
    Snyder CL; Gibson RS; Porter ML; Kimball AB
    Immunotherapy; 2023 Dec; 15(17):1449-1457. PubMed ID: 37840286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.